Immunogenicity of HIV-1 envelope glycoprotein oligomers.
about
A Blueprint for HIV Vaccine DiscoveryVaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protectionA next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodiesA novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environmentStabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoproteinThermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing AntibodiesElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinRecent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody responseA human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primatesEvolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection.Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchangeSoluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates.Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization.Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.Increased functional stability and homogeneity of viral envelope spikes through directed evolution.Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120.Structure-based vaccine design in HIV: blind men and the elephant?Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.Targeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapyImmunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C.Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer.Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine DesignStrategies for eliciting HIV-1 inhibitory antibodiesHIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation.Neutralizing antibodies to HIV-1 induced by immunization.Polyvalent AIDS vaccines.B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidatesRobust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates.Gene therapy as a vaccine for HIV-1.Envelope Glycoprotein Trimers as HIV-1 Vaccine ImmunogensHIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.Antigenic and immunosuppressive properties of a trimeric recombinant transmembrane envelope protein gp41 of HIV-1
P2860
Q26829865-60736D9E-5E98-4BEB-9572-6787FEEC494EQ27332360-3CF95A42-B6FE-4588-BFCA-8E50FDD1488EQ28299280-3C36EA4F-741F-4C64-8484-FDDE4F91A5C4Q28476693-44807D7C-7F8F-4D42-ABE3-E205E873F80EQ28534454-F46F6E6F-2BAF-4886-8374-D827DBD821E4Q28553360-BD5C92C4-F8FF-409F-B6B8-1B8CDBAC02BBQ28732438-BB27B3CB-B94E-4149-97E5-3F644150526CQ30353580-03915902-FD14-42B6-8A7C-E13CD8336720Q30490942-71FFB851-077B-4403-A318-56011554FA05Q31036522-7167FA55-969F-47D6-8173-505170D99646Q31132248-603AD019-420D-40AD-9836-03945D77C4CDQ33614605-5C296C04-01CE-4D21-9529-56D21BD4FAF5Q33809419-90559427-E9A2-4DB6-AE19-246542F2A30DQ34055984-076813E1-553D-48D6-BD87-69F8879A531AQ34096530-6B07C740-1C4C-4DCC-8693-146F4BD10C3CQ34120088-06A3CAE5-5AF2-48B4-8ABA-5269815B13B1Q34133551-11158C1A-D129-426B-A8E7-8ECCB89B3D84Q34284855-C39F9D3B-C02B-4996-877E-8AB94E81767EQ34594905-F35EA81E-5552-4E84-845F-A860A95F4A54Q34611144-C0A8AD7A-11E9-4052-A6E6-82028339BF06Q34625185-D6CAD058-B7B9-45C9-9161-13AEE57AEE54Q34885869-76C34920-0145-418E-8A50-43E040175216Q34987048-4F1310A1-8B7E-4D5C-98BB-B51F0B20446BQ35160124-7AE1940A-DEAE-42A7-A172-C9F80593249DQ35615810-4BB3A882-8224-4ED2-B225-858209C49ED4Q35745442-4CB60AF3-CBB5-4616-AFD8-5E8B2D3821C4Q35826171-6387718A-5AE7-4C31-85E4-2E31B3E52237Q36132706-DE391AE9-2AFE-4CBD-981E-AE3CC2CDFE6EQ36409575-381954FB-D360-4A06-A60B-775AECF40441Q36447540-ABDA0560-765D-4307-80AD-2A34F1424222Q36452155-574F1692-E590-486B-AA8D-BF21709C5D3AQ36583109-6656CB7B-E547-4527-BF23-57263D50DEBBQ36603515-675C7E0F-4AF8-4CD0-96DE-E1DA24EB5D54Q37094429-5A6C65AB-0D78-4BEA-9D2C-2E3B94C8C4E4Q37171260-85149401-E913-4310-93E9-6B3834852110Q37336704-103716FA-BA7D-480D-88CC-0A066A4045FEQ38026862-72A4E9F0-4D74-4A8D-A9EF-B0F30DED5184Q38581943-4C7A074A-39D3-4140-A459-F6501D3D462CQ38665463-65718BC4-700B-479B-849A-60B587D9AA51Q38914831-BCB2F2AA-3D7E-4FD0-8E94-33426EE07AEE
P2860
Immunogenicity of HIV-1 envelope glycoprotein oligomers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunogenicity of HIV-1 envelope glycoprotein oligomers.
@en
Immunogenicity of HIV-1 envelope glycoprotein oligomers.
@nl
type
label
Immunogenicity of HIV-1 envelope glycoprotein oligomers.
@en
Immunogenicity of HIV-1 envelope glycoprotein oligomers.
@nl
prefLabel
Immunogenicity of HIV-1 envelope glycoprotein oligomers.
@en
Immunogenicity of HIV-1 envelope glycoprotein oligomers.
@nl
P2093
P1476
Immunogenicity of HIV-1 envelope glycoprotein oligomers.
@en
P2093
Mattias N E Forsell
Richard T Wyatt
William R Schief
P304
P356
10.1097/COH.0B013E32832EDC19
P577
2009-09-01T00:00:00Z